VEGFA and retinopathy of prematurity: The Bevacizumab Eliminates the Angiogenic Threat of ROP (BEAT-ROP) trial demonstrated favorable outcomes of intravitreal anti-vascular endothelial growth factor (VEGF) therapy for type 1 ROP21.